Suppression of lysozyme aggregation at alkaline pH by tri-N-acetylchitotriose

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1794, Issue 6, 2009, Pages 913-920

  Kumar, Satish ^a   Ravi, Vijay Kumar ^a   Swaminathan, Rajaram ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

Amyloid fibril; Atomic force microscopy; Enzyme activity; Inhibitor; Protein stabilization; SDS PAGE; Thioflavin T

Indexed keywords

ASPARAGINE; ASPARTIC ACID; EGG WHITE; LYSOZYME; N,N',N''' TRIACETYLCHITOTRIOSE; TRI N ACETYLCHITOTRIOSE; TRIOSE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ALKALINITY; AMYLOIDOSIS; ANIMAL CELL; ARTICLE; ATOMIC FORCE MICROSCOPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ANALYSIS; HEN; NONHUMAN; PH MEASUREMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STABILITY;

CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ATOMIC FORCE; MURAMIDASE; TRISACCHARIDES;

EID: 67349219351     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.01.009     Document Type: Article

References (44)

1. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid and human disease. Annu. Rev. Biochem. 75 (2006) 333-366
2. Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta. 1739 (2004) 5-25
3. Rochet J.C. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Exp. Rev. Mol. Med. 9 (2007) 1-34
4. May B.C., Govaerts C., and Cohen F.E. Developing therapeutics for diseases of protein misfolding. Neurology 66 Suppl 1 (2006) S118-S122
5. Johnson S.M., Wiseman R.L., Sekijima Y., Green N.S., Adamski-Werner S.L., and Kelly J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38 (2005) 911-921
6. Hammarstrom P., Wiseman R.L., Powers E.T., and Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299 (2003) 713-716
7. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nature Med. 10 (2004) S10-S17
8. Bernier V., Lagace M., Bichet D.G., and Bouvier M. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol. Metab. 15 (2004) 222-228
9. Kumar S., Ravi V.K., and Swaminathan R. How do surfactants and DTT affect the size, dynamics, activity and growth of soluble lysozyme aggregates?. Biochem. J. 415 (2008) 275-288
10. Loo T.W., and Clarke D.M. Chemical and pharmacological chaperones as new therapeutic agents. Exp. Rev. Mol. Med. 9 (2007) 1-18
11. Papp E., and Csermely P. Chemical chaperones: mechanisms of action and potential use. Handb Exp. Pharmacol. 172 (2006) 405-416
12. Ray S.S., Nowak R.J., Brown Jr. R.H., and Lansbury Jr. P.T. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3639-3644
13. Miroy G.J., Lai Z., Lashuel H.A., Peterson S.A., Strang C., and Kelly J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 15051-15056
14. Soldi G., Plakoutsi G., Taddei N., and Chiti F. Stabilization of a native protein mediated by ligand binding inhibits amyloid formation independently of the aggregation pathway. J. Med. Chem. 49 (2006) 6057-6064
15. Tanaka M., Machida Y., and Nukina N. A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules. J. Mol. Med. 83 (2005) 343-352
16. Pepys M.B., Hawkins P.N., Booth D.R., Vigushin D.M., Tennent G.A., Soutar A.K., Totty N., Nguyen O., Blake C.C., Terry C.J., Feest T.G., Zalin A.M., and Hsuan J.J. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362 (1993) 553-557
17. Trexler A.J., and Nilsson M.R. The formation of amyloid fibrils from proteins in the lysozyme family. Curr. Protein Pept Sci. 8 (2007) 537-557
18. Homchaudhuri L., Kumar S., and Swaminathan R. Slow aggregation of lysozyme in alkaline pH monitored in real time employing the fluorescence anisotropy of covalently labeled dansyl probe. FEBS Lett. 580 (2006) 2097-2101
19. Wall J., Murphy C.L., and Solomon A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol. 309 (1999) 204-217
20. Davies R.C., Neuberger A., and Wilson B.M. The dependence of lysozyme activity on pH and ionic strength. Biochim. Biophys. Acta 178 (1969) 294-305
21. Dahlquist F.W., Jao L., and Raftery M. On the binding of chitin oligosaccharides to lysozyme. Proc. Natl. Acad. Sci. USA 56 (1966) 26-30
22. Rupley J.A., Butler L., Gerring M., Hartdegen F.J., and Pecoraro R. Studies on the enzymic activity of lysozyme, III. The binding of saccharides. Proc. Natl. Acad. Sci. U. S. A. 57 (1967) 1088-1095
23. Imoto T., Andrews L.J., Banerjee S.K., Shrake A., Forster L.S., and Rupley J.A. Optical properties of lysozyme. pH and saccharide binding difference spectra. J. Biol. Chem. 250 (1975) 8275-8282
24. Banerjee S.K., and Rupley J.A. Temperature and pH dependence of the binding of oligosaccharides to lysozyme. J. Biol. Chem. 248 (1973) 2117-2124
25. Kumagai I., Sunada F., Takeda S., and Miura K. Redesign of the substrate-binding site of hen egg white lysozyme based on the molecular evolution of C-type lysozymes. J. Biol. Chem. 267 (1992) 4608-4612
26. Stryer L. Fluorescence spectroscopy of proteins. Science 162 (1968) 526-533
27. LeVine III H. Thioflavin T interaction with synthetic Alzheimer's disease β amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 (1993) 404-410
28. Sophianopoulos A.J. Association sites of lysozyme in solution. The active site. J. Biol. Chem. 244 (1969) 3188-3193
29. Bjurulf C., Laynez J., and Wadso I. Thermochemistry of lysozyme-inhibitor binding. Eur. J. Biochem. 14 (1970) 47-52
30. Hameed M., Ahmad B., Fazili K.M., Andrabi K., and Khan R.H. Different molten globule-like folding intermediates of hen egg white lysozyme induced by high pH and tertiary butanol. J. Biochem. (Tokyo) 141 (2007) 573-583
31. Kuramitsu S., Ikeda K., Hamaguchi K., Miwa S., and Nakashima K. Binding of N-Acetyl-chitotriose to human lysozyme. J. Biochem. (Tokyo) 78 (1975) 327-333
32. Sophianopoulos A.J., and van Holde K.E. Evidence for dimerization of lysozyme in alkaline solution. J. Biol. Chem. 236 (1961) PC82-PC83
33. Krebs M.R., Wilkins D.K., Chung E.W., Pitkeathly M.C., Chamberlain A.K., Zurdo J., Robinson C.V., and Dobson C.M. Formation and seeding of amyloid fibril from wild type hen lysozyme and a peptide fragment from the β-domain. J. Mol. Biol. 300 (2000) 541-549
34. McAllister C., Karymov M.A., Kawano Y., Lushnikov A.Y., Mikheikin A., Uversky V.N., and Lyubchenko Y.L. Protein interactions and misfolding analyzed by AFM force spectroscopy. J. Mol. Biol. 354 (2005) 1028-1042
35. Sasahara K., Yagi H., Naiki H., and Goto Y. Heat-induced conversion of β2-microglobulin and hen egg-white lysozyme into amyloid fibrils. J. Mol. Biol. 372 (2007) 981-991
36. Goda S., Takano K., Yamagata Y., Nagata R., Akutsu H., Maki S., Namba K., and Yutani K. Amyloid protofilament formation of hen egg lysozyme in highly concentrated ethanol solution. Protein Sci. 9 (2000) 369-375
37. Movahedi A.A.M., Pirzadeh P., Hashemnia S., Ahmadian S., Hemmateenejad B., Amani M., Saboury A.A., Ahmad F., Shamsipur M., Hakimelahi G.H., et al. Fibril formation of lysozyme upon interaction with sodium dodecyl sulfate at pH 9.2. Colloid Surface B, 60 (2007) 55-61
38. van den Berg B., Ellis R.J., and Dobson C.M. Effects of macromolecular crowding on protein folding and aggregation. EMBO J. 18 (1999) 6927-6933
39. Vieira M.N., Figueroa-Villar J.D., Meirelles M.N., Ferreira S.T., and De Felice F.G. Small molecule inhibitors of lysozyme amyloid aggregation. Cell Biochem. Biophys. 44 (2006) 549-553
40. Zhou B.R., Zhou Z., Hu Q.L., Chen J., and Liang Y. Mixed macromolecular crowding inhibits amyloid formation of hen egg white lysozyme. Biochim. Biophys. Acta. 1784 (2008) 472-480
41. Morshedi D., Rezaei-Ghaleh N., Ebrahim-Habibi A., Ahmadian S., and Nemat-Gorgani M. Inhibition of amyloid fibrillation of lysozyme by indole derivatives-possible mechanism of action. FEBS J. 274 (2007) 6415-6425
42. Wang S.S.S., Chen P.H., and Hung Y.Tz. Effects of p-benzoquinone and melatonin on amyloid fibrillogenesis of hen egg-white lysozyme. J. Mol. Catal. B: Enzym. 43 (2006) 49-57
43. Lieu V.H., Wu J.W., Wang S.S., and Wu C.H. Inhibition of amyloid fibrillization of hen egg-white lysozymes by rifampicin and p-benzoquinone. Biotechnol. Prog. 23 (2007) 698-706
44. Gharibyan A.L., Zamotin V., Yanamandra K., Moskaleva O.S., Margulis B.A., Kostanyan I.A., and Morozova-Roche L.A. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J. Mol. Biol. 365 (2007) 1337-1349